DB:CNB

Stock Analysis Report

Executive Summary

Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products.

Rewards

Revenue is forecast to grow 38.3% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

Shareholders have been diluted in the past year



Snowflake Analysis

Adequate balance sheet with limited growth.


Similar Companies

Share Price & News

How has Fortress Biotech's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CNB's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.8%

CNB

1.3%

DE Biotechs

0.3%

DE Market


1 Year Return

165.0%

CNB

4.9%

DE Biotechs

13.8%

DE Market

Return vs Industry: CNB exceeded the German Biotechs industry which returned 5.3% over the past year.

Return vs Market: CNB exceeded the German Market which returned 17.1% over the past year.


Shareholder returns

CNBIndustryMarket
7 Day0.8%1.3%0.3%
30 Day15.5%-2.7%1.7%
90 Day112.5%12.0%5.7%
1 Year165.0%165.0%5.1%4.9%17.4%13.8%
3 Year9.0%9.0%54.5%52.8%15.9%5.7%
5 Year17.4%17.4%16.5%14.0%27.9%10.6%

Price Volatility Vs. Market

How volatile is Fortress Biotech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Fortress Biotech undervalued compared to its fair value and its price relative to the market?

7.12x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CNB's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CNB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CNB is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: CNB is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CNB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CNB is overvalued based on its PB Ratio (6.6x) compared to the DE Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Fortress Biotech forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

51.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CNB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CNB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CNB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CNB's revenue (38.3% per year) is forecast to grow faster than the German market (4.8% per year).

High Growth Revenue: CNB's revenue (38.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CNB's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Fortress Biotech performed over the past 5 years?

-14.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CNB is currently unprofitable.

Growing Profit Margin: CNB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CNB is unprofitable, and losses have increased over the past 5 years at a rate of -14.3% per year.

Accelerating Growth: Unable to compare CNB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CNB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: CNB has a negative Return on Equity (-137.78%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Fortress Biotech's financial position?


Financial Position Analysis

Short Term Liabilities: CNB's short term assets ($166.3M) exceed its short term liabilities ($46.9M).

Long Term Liabilities: CNB's short term assets ($166.3M) exceed its long term liabilities ($99.7M).


Debt to Equity History and Analysis

Debt Level: CNB's debt to equity ratio (118.5%) is considered high.

Reducing Debt: CNB's debt to equity ratio has increased from 20.2% to 118.5% over the past 5 years.


Balance Sheet

Inventory Level: CNB has a low level of unsold assets or inventory.

Debt Coverage by Assets: CNB's debt is covered by short term assets (assets are 1.9x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CNB has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CNB has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of -24.7% each year.


Next Steps

Dividend

What is Fortress Biotech's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate CNB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CNB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CNB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CNB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CNB's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Fortress Biotech's salary, the management and board of directors tenure and is there insider trading?

6.1yrs

Average management tenure


CEO

Lindsay Rosenwald (64yo)

6.1yrs

Tenure

US$2,371,474

Compensation

Dr. Lindsay Allan Rosenwald, M.D., serves as the Chairman of the Board of Directors at Avenue Therapeutics, Inc since February, 2015. He has been Executive Chairman, Chief Executive Officer and President o ...


CEO Compensation Analysis

Compensation vs Market: Lindsay's total compensation ($USD2.37M) is above average for companies of similar size in the German market ($USD638.09K).

Compensation vs Earnings: Lindsay's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

6.1yrs

Average Tenure

60.5yo

Average Age

Experienced Management: CNB's management team is seasoned and experienced (6.1 years average tenure).


Board Age and Tenure

6.1yrs

Average Tenure

63yo

Average Age

Experienced Board: CNB's board of directors are considered experienced (6.1 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Buy€2,25531 Dec 19
Robyn Hunter
EntityIndividual
Role
Chief Financial Officer
CFO, Treasurer & Corporate Secretary
Shares2,297
Max Price€0.98

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.1%.


Management Team

  • Mike Weiss (53yo)

    Executive Vice Chairman of Strategic Development & Director

    • Tenure: 6.1yrs
    • Compensation: US$2.37m
  • Lindsay Rosenwald (64yo)

    Executive Chairman

    • Tenure: 6.1yrs
    • Compensation: US$2.37m
  • Robyn Hunter (57yo)

    CFO, Treasurer & Corporate Secretary

    • Tenure: 2.6yrs
    • Compensation: US$479.62k
  • Thomas Schaible

    Project Leader of Inflammatory Bowel Disease

    • Tenure: 6.7yrs
  • George Avgerinos (65yo)

    Senior Vice President of Biologics Operations

    • Tenure: 6.6yrs
    • Compensation: US$385.98k

Board Members

  • Mike Weiss (53yo)

    Executive Vice Chairman of Strategic Development & Director

    • Tenure: 6.1yrs
    • Compensation: US$2.37m
  • Lindsay Rosenwald (64yo)

    Executive Chairman

    • Tenure: 6.1yrs
    • Compensation: US$2.37m
  • Malcolm Hoenlein (75yo)

    Independent Director

    • Tenure: 5.9yrs
    • Compensation: US$234.50k
  • Dov Klein (67yo)

    Independent Director

    • Tenure: 4.5yrs
    • Compensation: US$459.00k
  • Eric Rowinsky (62yo)

    Co-Vice Chairman

    • Tenure: 9.3yrs
    • Compensation: US$713.58k
  • J. Lobell (56yo)

    Independent Director

    • Tenure: 13.6yrs
    • Compensation: US$466.50k
  • David Elliott

    Scientific Advisor

    • Tenure: 2.6yrs
  • Joel Weinstock

    Scientific Advisor

    • Tenure: 2.6yrs
  • Mark Lowdell (56yo)

    Member of Scientific Advisory Board

    • Jimmie Harvey (67yo)

      Independent Director

      • Tenure: 11.1yrs
      • Compensation: US$446.50k

    Company Information

    Fortress Biotech, Inc.'s company bio, employee growth, exchange listings and data sources


    Key Information

    • Name: Fortress Biotech, Inc.
    • Ticker: CNB
    • Exchange: DB
    • Founded: 2006
    • Industry: Biotechnology
    • Sector: Pharmaceuticals & Biotech
    • Market Cap: US$184.736m
    • Listing Market Cap: US$167.537m
    • Shares outstanding: 70.78m
    • Website: https://www.fortressbiotech.com

    Number of Employees


    Location

    • Fortress Biotech, Inc.
    • 2 Gansevoort Street
    • 9th Floor
    • New York
    • New York
    • 10014
    • United States

    Listings

    TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
    FBIONasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 2011
    CNBDB (Deutsche Boerse AG)YesCommon StockDEEURNov 2011
    FBIO.PNasdaqCM (Nasdaq Capital Market)9.375% CUM PFD AUSUSDNov 2017

    Biography

    Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. It markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; Ala-Scalp and Triderm, which are used for the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; and Ala-Quin, an antibacterial and antifungal cream. The company also develops MB-107, a gene therapy for X-linked severe combined immunodeficiency; CAEL-101, a Phase Ia/Ib trial that reduces amyloid deposits in the tissues and organs; CD123 chimeric antigen receptor engineered T-cell (CAR T) program for acute myeloid leukemia; CD20 CAR T program for B cell non-Hodgkin lymphoma; and CS1 CAR T for multiple myeloma and light chain amyloidosis. In addition, it develops MB-101 for Glioblastoma (GBM); MB-103 for GBM, and breast cancer and brain metastases; MB-105 for prostate and pancreatic cancers; intravenous Tramadol for post-operative pain; CK-101, a Phase I/II clinical trial for treating patients with EGFR mutation-positive non-small cell lung cancer; CK-301, a Phase I clinical trial for metastatic cancer; Triplex, a Phase I study recombinant modified vaccinia ankara viral vector vaccine; ConVax, a recombinant modified vaccinia ankara viral vector vaccine; CEVA-101 for traumatic brain injury; CEVA-D, a bioreactor device that enhances the anti-inflammatory potency of bone marrow-derived cells; Tamid-001, a gene therapy for mucopolysaccharidosis type I disorder; CNDO-109, a lysate that activates donor natural killer cells; and methazalomide products. The company has collaboration arrangements with some universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York. 


    Company Analysis and Financial Data Status

    All financial data provided by Standard & Poor's Capital IQ.
    DataLast Updated (UTC time)
    Company Analysis2020/01/25 22:28
    End of Day Share Price2020/01/24 00:00
    Earnings2019/09/30
    Annual Earnings2018/12/31


    Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.